Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
09 04 2020
Historique:
received: 11 07 2019
accepted: 21 01 2020
pubmed: 11 2 2020
medline: 3 11 2020
entrez: 11 2 2020
Statut: ppublish

Résumé

In gene therapy with human hematopoietic stem and progenitor cells (HSPCs), each gene-corrected cell and its progeny are marked in a unique way by the integrating vector. This feature enables lineages to be tracked by sampling blood cells and using DNA sequencing to identify the vector integration sites. Here, we studied 5 cell lineages (granulocytes, monocytes, T cells, B cells, and natural killer cells) in patients having undergone HSPC gene therapy for Wiskott-Aldrich syndrome or β hemoglobinopathies. We found that the estimated minimum number of active, repopulating HSPCs (which ranged from 2000 to 50 000) was correlated with the number of HSPCs per kilogram infused. We sought to quantify the lineage output and dynamics of gene-modified clones; this is usually challenging because of sparse sampling of the various cell types during the analytical procedure, contamination during cell isolation, and different levels of vector marking in the various lineages. We therefore measured the residual contamination and corrected our statistical models accordingly to provide a rigorous analysis of the HSPC lineage output. A cluster analysis of the HSPC lineage output highlighted the existence of several stable, distinct differentiation programs, including myeloid-dominant, lymphoid-dominant, and balanced cell subsets. Our study evidenced the heterogeneous nature of the cell lineage output from HSPCs and provided methods for analyzing these complex data.

Identifiants

pubmed: 32040546
pii: S0006-4971(20)62115-2
doi: 10.1182/blood.2019002350
pmc: PMC7146019
doi:

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1219-1231

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI082020
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI117950
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI045008
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI052845
Pays : United States
Organisme : Wellcome Trust
ID : 090233/Z/09/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Haematologica. 2018 May;103(5):778-786
pubmed: 29472357
Blood. 2011 Apr 28;117(17):4420-4
pubmed: 21304104
Science. 2013 Aug 23;341(6148):1233151
pubmed: 23845947
Blood. 2012 Feb 23;119(8):1848-55
pubmed: 22228628
Cell Stem Cell. 2016 Jul 7;19(1):107-19
pubmed: 27237736
Blood. 2000 Dec 15;96(13):4185-93
pubmed: 11110690
PLoS One. 2009 Sep 22;4(9):e6972
pubmed: 19771180
Cell Stem Cell. 2010 Jan 8;6(1):48-58
pubmed: 20074534
Cell. 2013 Aug 29;154(5):1112-1126
pubmed: 23993099
Science. 2016 Jan 8;351(6269):aab2116
pubmed: 26541609
Cell Stem Cell. 2012 Feb 3;10(2):120-36
pubmed: 22305562
Nat Med. 2018 Nov;24(11):1683-1690
pubmed: 30275570
PLoS Biol. 2004 Aug;2(8):E234
pubmed: 15314653
Cell. 2016 Nov 17;167(5):1310-1322.e17
pubmed: 27863245
Blood. 2006 May 1;107(9):3772-8
pubmed: 16439684
JAMA. 2015 Apr 21;313(15):1550-63
pubmed: 25898053
Stem Cell Reports. 2017 Apr 11;8(4):977-990
pubmed: 28330619
Science. 2011 Jul 8;333(6039):218-21
pubmed: 21737740
Blood. 2011 Apr 28;117(17):4460-6
pubmed: 21343613
Nature. 2015 Oct 15;526(7573):351-60
pubmed: 26469046
Cell Stem Cell. 2014 Apr 3;14(4):473-85
pubmed: 24702996
Cell. 2002 Aug 23;110(4):521-9
pubmed: 12202041
Cell Stem Cell. 2007 Oct 11;1(4):416-27
pubmed: 18371378
Cell. 2005 Apr 22;121(2):295-306
pubmed: 15851035
Cell. 2008 Dec 12;135(6):1118-29
pubmed: 19062086
Blood. 2017 Mar 16;129(11):1448-1457
pubmed: 28087539
Genome Res. 2007 Aug;17(8):1186-94
pubmed: 17545577
N Engl J Med. 2018 Apr 19;378(16):1479-1493
pubmed: 29669226
Bioinformatics. 2012 Mar 15;28(6):755-62
pubmed: 22238265
Science. 2014 Sep 19;345(6203):1509-12
pubmed: 25237102
Blood. 2013 Oct 31;122(18):3129-37
pubmed: 24030380
Nature. 2014 Oct 16;514(7522):322-7
pubmed: 25296256
Exp Hematol. 2016 Jul;44(7):635-40
pubmed: 27090409
Cell. 2019 Mar 7;176(6):1325-1339.e22
pubmed: 30827679
Cell Stem Cell. 2007 Aug 16;1(2):218-29
pubmed: 18371352
Nat Biotechnol. 2011 Oct 02;29(10):928-33
pubmed: 21964413
Cell. 1997 Nov 28;91(5):661-72
pubmed: 9393859
Trends Cell Biol. 2015 Aug;25(8):459-67
pubmed: 26004869
Nature. 2000 Mar 9;404(6774):193-7
pubmed: 10724173
N Engl J Med. 2017 Mar 2;376(9):848-855
pubmed: 28249145
Nature. 2013 Apr 11;496(7444):229-32
pubmed: 23552896
Stem Cells. 2013 Oct;31(10):2162-71
pubmed: 23554255
Bone Marrow Transplant. 2015 Jul;50(7):886-91
pubmed: 25665044
J Exp Med. 2005 Apr 18;201(8):1307-18
pubmed: 15837815
Science. 2013 Aug 23;341(6148):1233158
pubmed: 23845948
Blood. 2002 Aug 15;100(4):1302-9
pubmed: 12149211
Stem Cells. 2015 Mar;33(3):976-87
pubmed: 25446279
Nature. 2015 Feb 26;518(7540):542-6
pubmed: 25686605
Nature. 2018 Sep;561(7724):473-478
pubmed: 30185910
Cell Stem Cell. 2014 Apr 3;14(4):486-499
pubmed: 24702997
Mol Ther Methods Clin Dev. 2016 Dec 18;4:17-26
pubmed: 28344988
Mol Ther Methods Clin Dev. 2016 Dec 18;4:39-49
pubmed: 28344990
Nat Cell Biol. 2018 Jun;20(6):710-720
pubmed: 29802403
N Engl J Med. 2001 Jan 18;344(3):175-81
pubmed: 11172139
Blood. 2001 Nov 15;98(10):2900-8
pubmed: 11698269
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1447-1456
pubmed: 30622181
Cell Stem Cell. 2013 Jul 3;13(1):102-16
pubmed: 23827712
Nature. 2017 Aug 24;548(7668):456-460
pubmed: 28813413
Haematologica. 2020 May;105(5):1240-1247
pubmed: 31537695
Nature. 2018 Jan 11;553(7687):212-216
pubmed: 29323290
Blood. 2008 Nov 15;112(10):4139-47
pubmed: 18772454
Blood. 2010 Jul 29;116(4):625-7
pubmed: 20410504

Auteurs

Emmanuelle Six (E)

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.
Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Agathe Guilloux (A)

Laboratoire de Mathématiques et Modélisation d'Evry, CNRS, Paris-Saclay University, Evry University, Evry, France.

Adeline Denis (A)

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.
Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Arnaud Lecoules (A)

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.
Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Alessandra Magnani (A)

Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.

Romain Vilette (R)

Laboratoire de Mathématiques et Modélisation d'Evry, CNRS, Paris-Saclay University, Evry University, Evry, France.

Frances Male (F)

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

Nicolas Cagnard (N)

Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.
Structure Fédérative de Recherche Necker, Bioinformatic Platform, Paris, France.

Marianne Delville (M)

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.
Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Elisa Magrin (E)

Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.

Laure Caccavelli (L)

Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.

Cécile Roudaut (C)

Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.

Clemence Plantier (C)

Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.

Steicy Sobrino (S)

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.
Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

John Gregg (J)

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

Christopher L Nobles (CL)

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

John K Everett (JK)

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

Salima Hacein-Bey-Abina (S)

Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Kremlin-Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicetre, France.
Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR 8258, INSERM U1267, Faculté de Pharmacie de Paris, Université Paris Descartes, Chimie ParisTech, Paris, France.

Anne Galy (A)

Genethon, Evry, France.
Inserm UMR S951, Evry University, Paris-Saclay University, Evry, France.

Alain Fischer (A)

Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.
Pediatric Hematology-Immunology and Rheumatology Unit, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
INSERM UMR 1163, Paris, France.
College de France, Paris, France; and.

Adrian J Thrasher (AJ)

Great Ormond Street, Institute of Child Health, Molecular and Cellular Immunology, University College London, United Kingdom.

Isabelle André (I)

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.
Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Marina Cavazzana (M)

INSERM UMR 1163, Laboratory of Human Lymphohematopoiesis, Paris, France.
Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.
Structure Fédérative de Recherche Necker, Bioinformatic Platform, Paris, France.

Frederic D Bushman (FD)

Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH